Medicines labeled for the same conditions
Alternatives to abiraterone
5 other medicines are given the same way (oral) and in the same FDA class as abiraterone or labeled mainly for the same use (prostate cancer); the others include 2 androgen receptor inhibitors, 1 poly(adp-ribose) polymerase inhibitor and 1 gonadotropin releasing hormone receptor antagonist (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as abiraterone?
Prostate cancer lists all 17 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Abirateronecytochrome p450 17a1 inhibitor | this medicine | 24 labelers | $0.774 per tablet 250 mg tablet | No | No current entry |
| Enzalutamideandrogen receptor inhibitor | Prostate cancer | none listed | n/a | No | No current entry |
| Rucaparib camsylatepoly(adp-ribose) polymerase inhibitor | Prostate cancer | none listed | n/a | No | No current entry |
| Apalutamide | Prostate cancer | none listed | n/a | No | No current entry |
| Nilutamideandrogen receptor inhibitor | Prostate cancer | 1 labeler | n/a | Yes | A presentation being discontinued |
| Relugolixgonadotropin releasing hormone receptor antagonist | Prostate cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Abiraterone: the full record
- label, generics, price, shortages, recalls
- Abiraterone vs enzalutamide
- two records side by side